Med- Postbiotics

Postbiotics for therapy of atopic dermatitis

Atopic dermatitis (AD) is the most common chronic skin disease, affecting 15-20% of children and 1-3% of adults. Since the 1970s, the incidence of AD has increased 2-3-fold - especially in industrialized countries. Currently, there is no effective therapy leading to complete remission of AD, and topical treatment with corticosteroids and calcineurin inhibitors focuses on symptom relief and achieving control of relapses. The moderate therapeutic efficacy of available drugs, significant side effects, and patient satisfaction data clearly indicate the need to develop new therapies.

Based on years of research on postbiotic metabolites produced by the human gut microbiota, we selected the compound JP-U228. It has extremely potent anti-inflammatory properties and a mechanism of action completely different from current anti-inflammatory drugs on the market. Conducted in vivo studies have confirmed exceptional activity on the skin after topical administration and indicated the possibility of using its therapeutic potential in the treatment of AD. We are currently conducting next-stage preclinical studies for a formulation containing JP-U228 oriented towards topical treatment of inflammatory skin conditions.